


個人履歷 Curriculum Vitae

基本資料 (Personal)

中文姓名 (Name)：王威傑 (Edy Kornelius)

研究領域 (Major research area)：內分泌代謝疾病，
糖尿病，甲狀腺疾病 (Endocrine and Metabolic
Diseases, Diabetes Mellitus, Thyroid Disorders)



學歷 EDUCATION			
學校名稱	學位	起迄年月	科技專長
中山醫學大學 (Chung Shan Medical University)	博士 (PhD)	2015-2018	醫學博士 Medical Doctorate
中山醫學大學 (Chung Shan Medical University)	醫學系 (Medicine)	2000-2007	醫學士 Bachelor of Medicine
現職 PROFESSIONAL APPOINTMENT			
服務機構及單位	職稱	起迄年月	
中華民國內分泌學會 The Endocrine Society of the Republic of China (Taiwan)	秘書長 Secretary-General	2025/5 迄今 May 2025 – Present	
中山醫學大學醫學系 School of Medicine, Chung Shan Medical University	副教授 Associate Professor	2023/2 迄今 February 2023 – Present	
中山醫學大學附設醫院 Chung Shan Medical University Hospital	西醫醫學教育主任 Director, Western Medicine Medical Education	2023/8 迄今 August 2023 – Present	

中山醫學大學附設醫院 Chung Shan Medical University Hospital	內分泌暨新陳代謝科主治醫師主任 Chief, Division of Endocrinology and Metabolism	2024/9 迄今 September 2024 – Present
中山醫學大學附設醫院 Chung Shan Medical University Hospital	一般內科主任 Chief, Department of General Internal Medicine	2020/8 迄今 August 2020 – Present
經歷 WORKING EXPERIENCE		
中山醫學大學附設醫院 Chung Shan Medical University Hospital	主治醫師 Visiting staff	2007/8 迄今 August 2020 – Present

❖ SCI 期刊論文發表

- Cheng CY, Lo SC, Huang CN, Yang YS, Wang YH, **Kornelius E.** Association Between GLP-1 Receptor Agonist Use and Epilepsy Risk in Type 2 Diabetes. *Neurology*. 2026 Jan 13;106(1):e214509. doi: 10.1212/WNL.0000000000214509. Epub 2025 Dec 10. PMID: 41370744.
- Yu WS, Huang JY, Lo SC, Huang CN, Yang YS, **Kornelius E.** Association of tirzepatide and the risk of suicide in a real-world cohort. *Front Psychiatry*. 2025 Nov 17;16:1626103. doi: 10.3389/fpsyt.2025.1626103. PMID: 41334076; PMCID: PMC12667738.
- **Kornelius E.**, Hu TH, Chiao CH, Hwang JS, Chan TC. Age-stratified optimal non-HDL cholesterol and all-cause mortality in a healthy Taiwanese population considering personal risk factors. *Int J Cardiol Cardiovasc Risk Prev*. 2025 Oct 26;27:200537. doi: 10.1016/j.ijcrp.2025.200537. PMID: 41216627; PMCID: PMC12597053.
- **Kornelius E.**, Lo SC, Yang YS, Wang YH, Huang CN. Comparative cardiovascular risks of canagliflozin and selective SGLT2 inhibitors in type 2 diabetes. *Front Pharmacol*. 2025 Oct 20;16:1686851. doi: 10.3389/fphar.2025.1686851. PMID: 41190032; PMCID: PMC12580561.
- **Kornelius E.** Letter by Kornelius Regarding Article, "Cardiovascular Disease in Anabolic Androgenic Steroid Users". *Circulation*. 2025 Oct 21;152(16):e295. doi: 10.1161/CIRCULATIONAHA.125.074873. Epub 2025 Oct 20. PMID: 41115164.
- **Kornelius E.** Letter by Kornelius Regarding Article, "Risk of Incident Atrial Fibrillation in Women With a History of Hypertensive Disorders of

Pregnancy: A Population-Based Retrospective Cohort Study". *Circulation*. 2025 Oct 14;152(15):e284. doi: 10.1161/CIRCULATIONAHA.125.074400. Epub 2025 Oct 13. PMID: 41082594.

- Chang SH, Hsin PH, Lin JJ, Yang YS, Lo SC, Huang CN, Wang YH, **Kornelius E.** Evaluating the association between gestational diabetes and neonatal hypoglycemia in Taiwan: a retrospective study of 2,149 pregnancies. *Front Endocrinol (Lausanne)*. 2025 Sep 4;16:1634074. doi: 10.3389/fendo.2025.1634074. PMID: 40979708; PMCID: PMC12443536.
- Chang YT, Lo SC, **Kornelius E.** Comment on Lee et al. Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity. *Diabetes Care* 2025;48:489-493. *Diabetes Care*. 2025 Sep 1;48(9):e107-e108. doi: 10.2337/dc25-0896. PMID: 40834250.
- **Kornelius E.** Letter by Kornelius Regarding Article, "Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial". *Circulation*. 2025 Aug 19;152(7):e64. doi: 10.1161/CIRCULATIONAHA.125.074107. Epub 2025 Aug 18. PMID: 40825062.
- Yeh YT, Lo SC, Huang CN, Yang YS, Liao PL, **Kornelius E.** Comparative cardiovascular outcomes of aripiprazole vs. risperidone in patients with type 2 diabetes and schizophrenia: a retrospective cohort study. *Front Pharmacol*. 2025 Jul 28;16:1617534. doi: 10.3389/fphar.2025.1617534. PMID: 40792205; PMCID: PMC12336492.
- **Kornelius E.** Letter by Kornelius Regarding Article, "Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure". *Circulation*. 2025 Aug 12;152(6):e63. doi: 10.1161/CIRCULATIONAHA.125.074076. Epub 2025 Aug 11. PMID: 40788976.
- **Kornelius E.** Comment on Pradhan et al. Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and the Prevention of Cirrhosis Among Patients With Type 2 Diabetes. *Diabetes Care* 2025;48:444-454. *Diabetes Care*. 2025 Aug 1;48(8):e101. doi: 10.2337/dc25-0451. PMID: 40690648.
- Liu HJ, Lo SC, Huang CN, Yang YS, Wang YH, **Kornelius E.** Association between bipolar disorder and diabetic ketoacidosis/hyperosmolar hyperglycemic state. *Sci Rep*. 2025 Jul 2;15(1):22701. doi: 10.1038/s41598-025-08087-y. PMID: 40596274; PMCID: PMC12217833.
- Chang EW, Huang JY, Lo SC, Huang CN, Yang YS, **Kornelius E.** Association between SGLT-2 inhibitors and suicide risk in type 2 diabetes and bipolar: a real-world cohort study. *Front Pharmacol*. 2025 Jun 11;16:1601118. doi: 10.3389/fphar.2025.1601118. PMID: 40567368; PMCID: PMC12188542.
- Tsou SH, Luo KS, Huang CN, **Kornelius E.**, Cheng IT, Hung HC, Hung YC, Lin CL, Hsu MY. Liraglutide Attenuates FFA-Induced Retinal Pigment Epithelium Dysfunction via AMPK Activation and Lipid

Homeostasis Regulation in ARPE-19 Cells. *Int J Mol Sci*. 2025 Apr 14;26(8):3704. doi: 10.3390/ijms26083704. PMID: 40332323; PMCID: PMC12027664.

- Cheng CY, Huang CN, Yang YS, **Kornelius E**. Comment on Christiaens et al. Diabetes Overtreatment and Hypoglycemia in Older Patients With Type 2 Diabetes on Insulin Therapy: Insights From the HYPOAGE Cohort Study. *Diabetes Care* 2025;48:61-66. *Diabetes Care*. 2025 May 1;48(5):e77-e78. doi: 10.2337/dc25-0071. PMID: 40273347.
- **Kornelius E**. Fracture Prevention with Infrequent Zoledronate in Women. *N Engl J Med*. 2025 Apr 17;392(15):1554-1555. doi: 10.1056/NEJMc2502046. PMID: 40239078.
- **Kornelius E**, Lo SC, Huang CN, Wang YH, Yang YS. Anxiety disorders in patients with thyroid nodules vs. thyroid cancer: a retrospective cohort study. *Front Endocrinol (Lausanne)*. 2025 Apr 1;16:1539442. doi: 10.3389/fendo.2025.1539442. PMID: 40235655; PMCID: PMC11996671.
- Lin TC, **Kornelius E**. Acute Decompensated Heart Failure in an Elderly Patient: A Rare Presentation of Toxic Nodular Goiter. *Am J Case Rep*. 2025 Apr 9;26:e947896. doi: 10.12659/AJCR.947896. PMID: 40202927; PMCID: PMC11997898.
- **Kornelius E**. Comment to: The association between trajectory of serum cholesterol, statin dosage, and the risk of recurrent biliary stone diseases. *J Formos Med Assoc*. 2025 Mar 27:S0929-6646(25)00141-X. doi: 10.1016/j.jfma.2025.03.023. Epub ahead of print. PMID: 40155284.
- **Kornelius E**. Comment to: Colchicine to prevent cardiovascular death after an acute myocardial infarction. *J Formos Med Assoc*. 2025 Mar 1:S0929-6646(25)00095-6. doi: 10.1016/j.jfma.2025.02.030. Epub ahead of print. PMID: 40024866.
- **Kornelius E**, Lo SC, Huang CN, Wang CC, Wang YH, Yang YS. Association of herpes zoster vaccination and cardiovascular risk in patients with diabetes: long-term insights from a retrospective cohort study. *BMJ Open*. 2025 Feb 18;15(2):e090428. doi: 10.1136/bmjopen-2024-090428. PMID: 39965942; PMCID: PMC11836834.
- Kuo CY, Tsou SH, **Kornelius E**, Chan KC, Chang KW, Li JC, Huang CN, Lin CL. The protective effects of liraglutide in reducing lipid droplets accumulation and myocardial fibrosis in diabetic cardiomyopathy. *Cell Mol Life Sci*. 2025 Jan 8;82(1):39. doi: 10.1007/s00018-024-05558-9. PMID: 39779525; PMCID: PMC11711727.
- **Kornelius E**, Huang JY, Lo SC, Huang CN, Yang YS. The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy. *Sci Rep*. 2024 Oct 18;14(1):24433. doi: 10.1038/s41598-024-75965-2. PMID: 39424950; PMCID: PMC11489776.
- Ni MH, Yang YS, Huang JY, Lo SC, Huang CN, **Kornelius E**. The association of depression and sleep disorders in patients with type 1 diabetes in Taiwan. *Medicine (Baltimore)*. 2024 Jul 19;103(29):e38969. doi: 10.1097/MD.00000000000038969. PMID: 39029051.
- **Kornelius E**, Lo SC, Huang CN, Wang CC, Wang YH, Yang YS. Assessing herpes zoster vaccine efficacy in patients with diabetes: A community-based cohort study. *J Med Virol*. 2024 May;96(5):e29667. doi: 10.1002/jmv.29667. PMID: 38738524.

- Yang YS, **Kornelius E**, Wang YH, Lo SC, Huang CN. Association of dipeptidyl peptidase-4 inhibitor and recurrent pancreatitis risk among patients with type 2 diabetes: A retrospective cohort study. *Front Pharmacol.* 2024 Jul 4;15:1341363. doi: 10.3389/fphar.2024.1341363. PMID: 39027329; PMCID: PMC11256048.
- Yang YS, **Kornelius E**, Lo SC, Wang YH, Huang CN. Aspirin and Risk of Specific Breast Cancer Subtype in Women with Diabetes. *J Womens Health (Larchmt).* 2023 Mar;32(3):341-346. doi: 10.1089/jwh.2022.0055. Epub 2023 Jan 3. PMID: 36602517.
- Huang LA, Lo SC, Yang YS, Huang CN, Wang CC, Wang YH, **Kornelius E**. Association of COVID-19 Infection with Subsequent Thyroid Dysfunction: An International Population-Based Propensity Score Matched Analysis. *Thyroid.* 2024 Apr;34(4):442-449. doi: 10.1089/thy.2023.0626. Epub 2024 Mar 20. PMID: 38407979.
- Lo SC, **Kornelius E**, Liao PL, Huang JY, Yang YS, Huang CN. Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: Real-world evidence from a nationwide cohort database. *Diabetes Res Clin Pract.* 2023 Jun;200:110685. doi: 10.1016/j.diabres.2023.110685. Epub 2023 Apr 24. PMID: 37100230.
- Ho CC, Yang YS, Huang CN, Lo SC, Wang YH, **Kornelius E**. The efficacy of pioglitazone for renal protection in diabetic kidney disease. *PLoS One.* 2022 Feb 17;17(2):e0264129. doi: 10.1371/journal.pone.0264129. eCollection 2022.
- **Kornelius E**, Huang CN, Lo SC, Wang YH, Yang YS. Dipeptidyl-Peptidase 4 Inhibitors did not Improve Renal Endpoints in Advanced Diabetic Kidney Disease. *Endocr Pract.* 2020 Dec;26(12):1486-1496. doi: 10.4158/EP-2020-0143
- **Kornelius E**, Lo SC, Huang CN, Wang YH, Yang YS. Association of blood glucose and renal end points in advanced diabetic kidney disease. *Diabetes Res Clin Pract.* 2020 Jan 25;161:108011. doi: 10.1016/j.diabres.2020.108011.
- **Kornelius E**, Lo SC, Huang CN, Yang YS. The Risk of Thyroid Cancer in Patients with Thyroid Nodule 3 Cm Or Larger. *Endocr Pract.* 2020 Nov;26(11):1286-1290. doi: 10.4158/EP-2020-0136
- Chao HY, **Kornelius E**. Two alcoholic liver cirrhosis patients developed diabetic ketoacidosis after SGLT2 inhibitors-prescription. *J Formos Med Assoc.* 2020 Dec;119(12):1886-1887. doi: 10.1016/j.jfma.2020.07.013. Epub 2020 Jul 18.
- **Kornelius E**, Chang KL, Yang YS, Huang JY, Ku MS, Lee KY, Ho SW. Epidemiology and factors associated with mortality of thyroid storm in Taiwan: a nationwide population-based study. *Intern Emerg Med.* 2021;16:601-607
-

Beyond Glycemic Control: Emerging Neuroprotective Roles of GLP-1 Receptor Agonists

控糖之外：GLP-1 受體促效劑在神經保護上的新興角色

王威傑

中山醫學大學附設醫院

內分泌暨新陳代謝科主任

Glucagon-like peptide-1 receptor agonists (GLP-1RA) are well established as effective glucose-lowering agents with robust evidence supporting their cardiovascular and renal benefits in patients with type 2 diabetes. Increasing attention has recently focused on their potential pleiotropic effects beyond glycemic control, particularly within the central nervous system. GLP-1 receptors are widely expressed in the brain, including regions critical for cognition and motor function such as the hippocampus, cortex, and substantia nigra, providing a mechanistic basis for potential neuroprotective effects.

Preclinical studies have demonstrated that GLP-1RA may attenuate neuroinflammation, reduce oxidative stress, improve mitochondrial function, and enhance neuronal survival and synaptic plasticity. These mechanisms are closely linked to the pathophysiology of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. Early-phase clinical trials, particularly those evaluating exenatide in Parkinson's disease, have suggested possible disease-modifying effects, although findings remain preliminary. In addition, data from large cardiovascular outcome trials have indicated potential reductions in stroke and signals toward improved cognitive outcomes.

Real-world evidence has further expanded this field, with observational studies suggesting associations between GLP-1RA use and reduced risks of dementia, epilepsy, and certain neuropsychiatric conditions. Nevertheless, these findings should be interpreted with caution due to inherent limitations, including residual confounding, heterogeneity among different GLP-1RA compounds, and the absence of dedicated randomized controlled trials specifically targeting neurological endpoints.

In conclusion, GLP-1RA represent a promising therapeutic class with emerging roles in neurodegenerative and neurological diseases. While current evidence remains exploratory, ongoing and future large-scale clinical trials will be essential to determine whether these agents can be translated into effective neuroprotective therapies in clinical practice.